CLS-AX (axitinib injectable suspension)
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
Phase 3Phase 3-ready; Phase 2b (ODYSSEY) completed
Key Facts
Indication
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
Phase
Phase 3
Status
Phase 3-ready; Phase 2b (ODYSSEY) completed
Company
About Clearside Biomedical
Clearside Biomedical is revolutionizing the treatment of sight-threatening retinal diseases by developing and commercializing therapies delivered through its proprietary suprachoroidal space (SCS) injection platform. The company has validated its technology with the FDA-approved product XIPERE® for uveitic macular edema and is advancing its lead candidate, CLS-AX (axitinib), into Phase 3 trials for wet AMD. Clearside leverages strategic partnerships to expand its pipeline and commercial reach, positioning itself as the leader in targeted ocular drug delivery.
View full company profile